Vireo Growth (VREOF) Return on Capital Employed (2021 - 2026)
Vireo Growth (VREOF) posted Return on Capital Employed of 0.91% for Q1 2026, up 593.95% sequentially from 0.18% in Q4 2025, and down 679.0% YoY from 0.16% in Q1 2025.
Vireo Growth (VREOF) Return on Capital Employed (2021 - 2026) Analysis & Trends
Vireo Growth has reported Return on Capital Employed for 6 years, with the latest figure at 0.91% in Q1 2026.
- Quarterly Return on Capital Employed fell 679.0% year-over-year to 0.91% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.91% (down 679.0% YoY) and the FY2025 annual result came in at 0.29%, down 1448.0% from the prior year.
- Return on Capital Employed advanced to 0.91% in Q1 2026 per VREOF's latest filing, from 0.18% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 527.87% in Q1 2024 and troughed at 528.74% in Q4 2023.
- A 5-year average of 31.89% and a median of 0.91% in 2026 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed tumbled 52365 bps in 2023, then surged 54218 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 5.08% in 2022, then slumped by 10303 bps to 528.74% in 2023, then soared by 103 bps to 13.44% in 2024, then sank by 101 bps to 0.18% in 2025, then soared by 594 bps to 0.91% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 0.91%, 0.18%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | 0.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.91% |
| Dec 31, 2025 | -0.18% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | 1.33% |
| Mar 31, 2025 | 7.70% |
| Dec 31, 2024 | 13.44% |
| Sep 30, 2024 | 30.21% |
| Jun 30, 2024 | 362.84% |
| Mar 31, 2024 | 527.87% |
| Dec 31, 2023 | -528.74% |
| Sep 30, 2023 | 173.96% |
| Jun 30, 2023 | -3.04% |
| Mar 31, 2023 | 1.87% |
| Dec 31, 2022 | -5.08% |
| Sep 30, 2022 | -10.99% |
| Jun 30, 2022 | -13.57% |
| Mar 31, 2022 | -16.32% |
| Dec 31, 2021 | -13.73% |
| Sep 30, 2021 | -11.73% |
| Jun 30, 2021 | -12.35% |